In recent years, use of targeted therapy against human epidermal growth factor receptor-2 (HER2) and immunotherapy against programmed cell death protein-1 (PD-1) have resulted in progress in the treatment of advanced gastric cancer. Here, PDCD1 is linked to gastric cancer.